Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 395832 NeurOMEGA

ARTG entry for Medicine Listed

Sponsor Bio-Practica Pty Ltd

Postal Address 651 Portrush Road, GLEN OSMOND, SA, 5064

Australia

ARTG Start Date 12/09/2022
Product Category Medicine
Status Active

Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. NeurOMEGA

Product Type Single Medicine Product **Effective Date** 9/03/2023

Permitted Indications

Helps maintain/support healthy eye development in infants

Maintain/support healthy growth and development

Maintain/support general health and wellbeing

Maintain/support healthy teeth

Maintain/support bone health

Aids/assists healthy bone development/growth/building

Help maintain/support bone mineralisation

Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life

Maintain/support cardiovascular system health

Maintain/support immune system health

Maintain/support healthy immune system function

Maintain/support muscle health

Maintain/support muscle function

Maintain/support healthy neuromuscular system/function

Aid/assist/helps glucose/sugar/carbohydrate metabolism

Maintain/support absorption of dietary (state vitamin/mineral/nutrient)

 ${\it Maintain/support\ (state\ vitamin/mineral/nutrient)\ levels\ in\ the\ body}$

Helps prevent dietary (state vitamin/mineral/nutrient) deficiency

Maintain/support cognitive function/mental function

Maintain/support brain health

Maintain/support nervous system health

Maintain/support brain/central nervous system development in infants

Maintain/support nervous system function

Indication Requirements

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Page 1 of 2



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR

[Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

Product presentation must not imply or refer to neurological conditions or developmental delays.

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to serious immunological diseases.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, soft

Route of Administration Oral

Visual Identification

Active Ingredients

colecalciferol12.5 microgramDHA/EPA rich Schizochytrium algal oil962.7 mgEquivalent: docosahexaenoic acid300 mgEquivalent: eicosapentaenoic acid150 mg

Other Ingredients (Excipients)

ascorbyl palmitate

carrageenan

d-alpha-tocopherol

glycerol

hydroxypropyl starch

medium chain triglycerides

mixed (low-alpha type) tocopherols concentrate

purified water

Rosemary Oil

sodium carbonate

Sunflower Oil

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.